SCHEMBL7231065

SCHEMBL7231065

COc1ccnc(-c2ccc3ccc(Cl)nc3c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.53
CCR5 P51681 1/20 0.53
CCR8 P51685 1/20 0.53
NPC1 O15118 6/20 0.43
RAB9A P51151 6/20 0.43
CASP3 P42574 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
PIK3CG P48736 1/20 0.39
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
SYK P43405 1/20 0.39
CBFB Q13951 2/20 0.38
CYP1A1 P04798 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2E1 P05181 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C8 P10632 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7238319 0.84 CCR1 (0.51) CCR1CCR5CCR8NPC1RAB9A
Hydrochloric Acid SCHEMBL7240213 0.81 CCR1 (0.50) CCR1CCR5CCR8NPC1RAB9A
SCHEMBL622376 0.78 ALDH1A1 (0.56) NPC1RAB9ACYP1A2CYP2A6ALDH1A1
Hydrochloric Acid SCHEMBL7229406 0.77 CCR1 (0.49) CCR1CCR5CCR8NPC1RAB9A
SCHEMBL7231567 0.77 CCR1 (0.66) CCR1CCR5CCR8NPC1RAB9A
SCHEMBL12885503 0.74 CCR1 (0.56) CCR1CCR5CCR8NPC1RAB9A
SCHEMBL7228502 0.74 CCR1 (0.56) CCR1CCR5CCR8NPC1RAB9A
SCHEMBL30913199 0.73 CCR1 (0.59) CCR1CCR5CCR8NOS3NOS1
SCHEMBL29282120 0.73 CCR1 (0.59) CCR1CCR5CCR8NOS3NOS1
SCHEMBL182529 0.72 CCR1 (1.00) CCR1CCR5CCR8NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6521643-B1 Prevention and/or treatment of nitric oxide synthasey medi-ated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, diabetes, ulcerative colitis, cerebral infarction, osteoarthritis FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-02-18 US disclosed
EP-1157022-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-28 EP disclosed
WO-2000049015-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-08-24 WO disclosed